血浆总tau水平作为痴呆预测生物标志物的评估
该前瞻性队列研究基于美国Framingham心脏研究(1453人)并在法国Memento队列(367人)中重复验证,发现血浆总tau每升高1个SD(对数尺度)与AD痴呆风险增加35%相关(HR 1.35,95%CI 1.10-1.67),且与认知表现、海马体积及尸检神经原纤维缠结和微梗死相关。
要点
- 血浆总tau可改善基于年龄和性别的AD痴呆风险分层(NRI 0.382)。
- 血浆总tau与多个认知任务表现、海马体积及尸检病理相关。
- 在重复队列中,血浆总tau与AD痴呆的关联不弱于脑脊液总tau。
核心结论
- 血浆总tau水平可能改善未来痴呆的预测,并与痴呆内表型相关,或可用于痴呆预防试验的风险分层。
研究设计与样本
- 前瞻性队列研究,使用美国社区Framingham心脏研究数据,并在法国记忆门诊招募的Memento队列(轻度认知障碍或主观认知抱怨者)中重复验证。
- Framingham样本1453人,平均年龄75(7)岁,女性792人(54.5%);Memento重复队列367人,平均年龄69(9)岁,女性217人(59.1%)。
- Framingham血浆样本于2004至2011年检测,痴呆随访中位6年(IQR 5-8年);Memento样本于2011年4月19日至2016年6月22日获取,随访中位4年(IQR 3-5年)。
主要发现
- Framingham样本发生134例全因痴呆,其中105例为AD痴呆。
- 年龄和性别调整后,对数血浆总tau每增加1个SD,AD痴呆风险增加35%(HR 1.35;95%CI 1.10-1.67)。
- 将血浆总tau加入年龄和性别模型改善AD痴呆风险分层(NRI 0.382;95%CI 0.030-0.716)。
- 较高的血浆总tau与7项认知任务表现较差(P < .05)、海马体积较小(β [SE] = 0.002 [0.001];P = .003)、尸检神经原纤维缠结(β [SE] = 0.95 [0.45];P = .04)及微梗死(OR 3.04;95%CI 1.26-7.37)相关。
- 重复队列中,血浆总tau与脑脊液总tau弱相关(Spearman相关系数0.16;P = .07),但年龄和性别调整后血浆总tau与 incident AD痴呆的关联(对数血浆总tau:HR 2.33;95%CI 1.00-5.48)不弱于脑脊液总tau(对数脑脊液总tau:HR 2.14;95%CI 1.33-3.44)。
临床怎么用
- 血浆总tau或可作为无创、低成本的筛查工具,辅助识别痴呆预防试验的高风险人群。
- 在记忆门诊或社区老年人群中,血浆总tau可结合年龄和性别改善AD痴呆风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Blood-based biomarkers have the potential to improve the identification of persons with the greatest dementia risk for inclusion in dementia prevention trials through low-cost and minimally invasive screening. OBJECTIVE: To investigate the use of plasma total tau as a blood biomarker for dementia and related endophenotypes. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study used data from the US community-based Framingham Heart Study with replication in the Memento study, a multicenter cohort of persons with mild cognitive impairment or subjective cognitive complaints recruited from memory clinics across France. Total tau levels were measured from stored plasma samples in Framingham Heart Study participants during 2004 to 2011. Dementia follow-up occurred across a median of 6 years (interquartile range, 5-8 years) for persons 65 years and older who were dementia free at baseline. Plasma and/or cerebrospinal fluid samples were obtained from Memento study participants from April 19, 2011, to June 22, 2016. Dementia follow-up took place over a median of 4 years (interquartile range, 3-5 years). Data analysis was performed from January to November 2018. EXPOSURES: Plasma total tau level measured using single-molecule array technology. MAIN OUTCOMES AND MEASURES: Incidence of dementia of any cause (all dementia) and dementia due to clinical Alzheimer disease (AD dementia). RESULTS: Among the 1453 participants in the Framingham dementia study sample, the mean (SD) age was 75 (7) years; 792 (54.5%) were female. Among the 367 individuals in the replication cohort, the mean (SD) age was 69 (9) years; 217 (59.1%) were female. Of 134 cases of incident all dementia in the Framingham sample, 105 were AD dementia. After adjustment for age and sex, each SD unit increase in the log of plasma total tau level was associated with a 35% increase in AD dementia risk (hazard ratio [HR], 1.35; 95% CI, 1.10-1.67). The addition of plasma total tau to a model including age and sex improved the stratification of participants for risk of AD dementia (net reclassification improvement, 0.382; 95% CI, 0.030-0.716). Higher plasma total tau level was associated with poorer cognition across 7 cognitive tasks (P < .05) and smaller hippocampi (hippocampal volume: β [SE] = 0.002 [0.001]; P = .003) as well as neurofibrillary tangles (β [SE] = 0.95 [0.45]; P = .04) and microinfarcts (odds ratio, 3.04; 95% CI, 1.26-7.37) at autopsy. In the replication cohort, plasma total tau level weakly correlated with cerebrospinal fluid total tau level (Spearman correlation coefficient, 0.16; P = .07), but plasma total tau was at least as strongly associated with incident AD dementia as cerebrospinal fluid total tau (log plasma total tau: HR, 2.33; 95% CI, 1.00-5.48; log cerebrospinal fluid total tau: HR, 2.14; 95% CI, 1.33-3.44) after adjustment for age and sex. CONCLUSIONS AND RELEVANCE: The findings suggest that plasma total tau levels may improve the prediction of future dementia, are associated with dementia endophenotypes, and may be used as a biomarker for risk stratification in dementia prevention trials.
引用
- Pase MP, Beiser AS, Himali JJ, et al. Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes. JAMA Neurol. 2019. PMID: 30830207. doi:10.1001/jamaneurol.2018.4666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。